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Background: The relationship between severe traumatic brain injury (TBI) and blood levels of matrix
metalloproteinase-9 (MMP-9) or cellular fibronectin (c-Fn) has never been reported. In this study, we aimed to
assess whether plasma concentrations of MMP-9 and c-Fn could have predictive values for the composite endpoint
of intensive care unit (ICU) length of stay (LOS) of survivors and mortality after severe TBI. Secondary outcomes
were the state of consciousness measured with the Glasgow Coma Scale (GCS) of survivors at 14 days and Glasgow
Outcome Scale Extended (GOSE) at 3 months.
Methods: Forty-nine patients with abbreviated injury scores of the head region ≥ 4 were included. Blood was
sampled at 6, 12, 24 and 48 hours after injury. MMP-9 and c-Fn concentrations were measured by ELISA. The values
of MMP-9 and c-Fn, and, for comparison, the value of the GCS on the field of the accident (fGCS), as predictors of
the composite outcome of ICU LOS and death were assessed by logistic regression.
Results: There was a linear relationship between maximal MMP-9 concentration, measured during the 6-12-hour
period, and maximal c-Fn concentration, measured during the 24-48-hour period. The risk of staying longer than
9 days in the ICU or of dying was increased in patients with a maximal early MMP-9 concentration ≥ 21.6 ng/ml
(OR = 5.0; 95% CI: 1.3 to 18.6; p = 0.02) or with a maximal late c-Fn concentration ≥ 7.7 μg/ml (OR = 5.4; 95%
CI: 1.4 to 20.8; p = 0.01). A similar risk association was observed with fGCS ≤8 (OR, 4.4; 95% CI, 1.2-15.8; p = 0.02).
No relationship was observed between MMP-9, c-Fn concentrations or fGCS and the GCS at 14 days of survivors
and GOSE at 3 months.
Conclusions: Plasma MMP-9 and c-Fn concentrations in the first 48 hours after injury are predictive for the
composite endpoint of ICU LOS and death after severe TBI but not for consciousness at 14 days and outcome at
3 months.
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The personal and societal consequences of severe trau-
matic brain injury (TBI) are considerable related to its
high rate of occurrence of cognitive dysfunction and dis-
ability [1,2]. Its estimated incidence in Europe is between
9–17 per 100'000 person/year [3,4]. The majority of
patients are men with a mean age of 40 to 50 years,
injured by falls or road traffic accidents [5,6]. The out-
come after severe TBI is often unfavorable with one third
to one half of patients dying during the 6 following
months and one third presenting severe disabilities [6-8].
In recent years validated models were developed to predict
poor outcome after TBI [9]. However, predictive power
when using such clinical models for individual patients
is still limited. All these models use components of the
Glasgow Coma Scale (GCS) which is known to have a
large inter-individual assessment range [10] and which
may explain this limited prediction capacity for individual
patients. One research direction in patients with TBI is
the attempt to improve these clinical prediction models
and to improve overall management via new diagnostic
assessments. Neuronal, glial and inflammatory biomarkers
were tested to add supplementary information on diagno-
sis and to provide early information about prognosis on
functional and cognitive outcome [11-18]. Among all
these biomarkers, S100b, a calcium binding protein with
high expression in astrocytes, has been the most exten-
sively investigated. S100b levels predicted mortality or
poor outcome [11,19].
Matrix metalloproteinases (MMP) are a family of zinc-
dependent endopeptidases involved in a number of
neurological diseases, in which neuroinflammation plays
a significant role [20]. MMP-9 degrades components of
the basal lamina, such as fibronectin and collagen-IV,
leading to disruption of the blood–brain barrier and
vasogenic brain edema [21-23]. Elevated brain MMP-9
concentration was found in experimental TBI [24-26]
and brain lesion volumes were significantly reduced in
TBI animals after overexpression of tissue inhibitor of
metallaloproteinases-1 or genetic knocked-out of the
mmp-9 gene [27,28]. Recently, it was described an acute
elevation of MMP-9 concentration in the cerebrospinal
fluid of six severe TBI patients as compared to normal
pressure hydrocephalus patients, but no differences in
plasma concentration between these two groups of
patients were observed [29]. Two other studies, carried
out on a limited number of patients, showed elevated
MMP-9 concentration in the plasma [30,31] and in the
brain extracellular fluid [31] during the acute stage of TBI.
Fibronectins are adhesive glycoproteins that promote
cell–cell and cell–matrix interactions [32]. Two forms of
fibronectins exist: plasma fibronectin, a dimeric and sol-
uble form secreted by hepatocytes directly into the cir-
culation, and cellular fibronectin (c-Fn), a multimericform assembled into fibrils and found in the extracellu-
lar matrix [33]. Because c-Fn is incorporated between
endothelial cells and pericytes [34], high plasma levels of
this molecule in TBI patients might be indicative of the
loss of blood brain barrier integrity. Elevated concentra-
tions of c-Fn were detected in the plasma after major
abdominal, thoracic or pulmonary traumatic injury [35].
However, to our knowledge, no study has reported the
release of c-Fn into the circulation after TBI.
Blood levels of MMP-9 and c-Fn have good predictive
values for the evaluation of hemorrhagic transformation
after thrombolytic therapy in acute ischemic stroke [36].
However, the relationship between TBI outcome and
blood levels of MMP-9 and c-Fn has never been reported.
In this study, we investigated the hypothesis that plasma
MMP-9 and c-Fn concentrations could play also a role in
TBI patients in the early period after injury, and, in par-
ticular, could have a predictive value for certain outcomes
such as intensive care unit (ICU) length of stay (LOS) and
mortality after severe TBI.Methods
Patients
We analysed the data of consecutive patients enrolled in
a prospective study on “Patient-relevant Endpoints after
Brain Injury from Traumatic Accidents” between May
2007 and November 2009. The study was approved by
the ethical committee of the Geneva University Hospital,
Geneva, Switzerland and was a follow up investigation of
our previous study [8]. Written informed consent by
proxy within 14 days after injury replaced informed con-
sent by patients, who were all severely injured at the
time of enrolment.
Patients with TBI from blunt trauma were enrolled
and included if severe TBI was confirmed by cerebral
CT scan. Severe TBI was defined by the presence of an
abbreviated injury scores (AIS) of the head region
(HAIS) ≥ 4 within the first 24 hours (first cerebral CT
or following CT within 24 hours after injury). For AIS
assessment, we used the 1990 revision, update 1998 [37].
On the 6-point scale of AIS, values of 4 to 6 correspond
to severe to fatal lesions.Outcomes
The primary outcome was the composite endpoint ICU
LOS for survivors and mortality in the ICU.
Secondary outcomes included ICU LOS for survivors,
mortality before 3 months, the state of consciousness
(Glasgow Coma Scale) at 14 days (GCS > 8 = conscious)
and Glasgow Outcome Scale Extended (GOSE) at 3
months [38]. Contrary to the hospital LOS where readi-
ness of discharge and real discharge may be different,
patients always left the ICU without delay; i.e. when their
Table 1 Clinical characteristics of the cohort
Characteristics of the cohort Values n
Age (years) 39 (25–55) 49
Height (m) 1.75 (1.70–1.80) 29
Weight (kg) 70 (66–80) 31
GCS on scene 7.0 (3.0–10.0) 49
Abnormal pupil reaction on scene 18/45 (40.0%) 45
Alcohol smell 15/46 (32.6%) 46
Intubation on scene 38/49 (77.6%) 49
GCS in emergency department 3.0 (3.0 – 3.0) 46
Abnormal pupil reaction in
emergency department
18/46 (39.1%) 46
SAPS II 52.0 (44.5–56.5) 39
ISS 29 (25–34) 49
Mortality at 14 days 11/49 (22.4%) 49
GCS at 14 days 11.0 (3.0–15.0) 49
GCS of survivors at 14 days 13.5 (8.0–15.0) 38
Abnormal pupil reaction of
survivors at 14 days
4/34 (11.8%) 34
Mortality at 3 months 15/49 (30.6%) 49
GOSE at 3 months 3.0 (1.0–4.0) 37
GOSE of survivors at 3 months 3.5 (3.0–4.0) 22
LOS of survivors in ICU (days) 9.0 (4.0–15.0) 37
LOS of survivors in acute hospital (days) 15.5 (10.0–24.5) 36








6 25.9 (9.8–60.1) 3.3 (2.4–6.1) 26
12 16.1 (7.8–31.2) 0.01 4.4 (2.6–6.3) 0.17 40
24 9.3 (5.2–20.0) 0.02 5.3 (2.7–8.5) 0.0001 45
48 6.4 (1.4–19.3) 0.0008 5.3 (3.5–9.3) 0.005 35
* As compared to the 6-hour time point.
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Therefore, this ICU LOS as endpoint was investigated.
Predictive factors
The relationships between the potential predictive fac-
tors MMP-9, c-Fn and the established predictive factor
GCS on the field of the accident (fGCS), as reported
by out of hospital emergency medical services were
assessed [39].
In addition, other early clinical and radiological para-
meters such as cerebral edema, midline shift, subarach-
noid hemorrhage (SAH), intraventricular hemorrhage
(IVH) or abnormal pupil reactions on the field of the
accident were assessed.
MMP-9 and c-Fn enzyme-linked immunosorbent assays
Blood was sampled at 6, 12, 24 and 48 hours after injury
in EDTA tubes and centrifuged. Plasma was stored at
−80°C until analysis. Plasma MMP-9 and c-Fn concen-
trations were measured blindly by enzyme-linked im-
munosorbent assays (biotrack Elisa system, Amersham
#RPN2614; Elisa kit for human c-Fn, Biohit Oyj #603010)
according to the manufacturer’s instructions.
Statistical analysis
Data were expressed as medians (interquartile ranges).
Boxplots show median values, lower and upper quartiles,
and the largest and smallest observed values (whiskers)
if the values lay within 2.5 time the interquartile range.
Multiple group comparisons of related samples were
done using the Friedman's 2-Way ANOVA by Ranks test
followed by Wilcoxon Matched-Pair Signed-Rank tests.
Independent samples were compared using the Mann–
Whitney U test for 2 samples. Linear regression was used
to assess the relationship between MMP-9 and c-Fn
concentrations. Receiver operating characteristic (ROC)
curves and logistic regression were used to assess the
values of MMP-9, c-Fn and fGCS as predictors of pro-
longed ICU stay or death and to determine odds ratios
(OR) and sensitivity/specificity. Statistical analyses were
performed with PASW Statistics release 18 for the Macin-
tosh. P < 0.05 was considered significant. ROC curve ana-
lyses were performed with the pROC package for TIBCO
Spotfire S+ version 8.2 for Windows. Comparison between
paired ROC curves were computed with the bootstrap test
and 10 000 replicates as described previously [40].
Results
Clinical characteristics of the cohort and outcome
Forty-nine patients were included (13 patients (27%)
with a HAIS of 4 and 36 patients (73%) with a HAIS of
5). The median fGCS was 7 (3–10) and 40.0% of the
patients had abnormal pupil reaction (Table 1). The me-
dian age of the cohort was 39 years (26–55). Six patients(12%) had multiple traumas with an AIS of the chest
region of 4 (5 patients: 4 died, 1 survived) or an AIS of
the abdomen region of 4 (1 patient who survived).
The median ICU LOS of the survivors was 9.0 days
(4.0-15.0); median hospital LOS was 15.5 days (10.0–
24.5). Fifteen patients (30.6%) died before 3 months. The
median GCS of the survivors at 14 days was 13.5 (8–15).
The median GOSE of the survivors at 3 month was
3.5 (3–4).
Temporal profiles of plasma MMP-9 and c-Fn
concentrations
Six hours after TBI, plasma MMP-9 concentration was
25.9 ng/ml (9.8–60.1) (Table 2). MMP-9 concentration
decreased significantly over the next days, to reach a
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3.3 μg/ml (2.4-6.1) (Table 2). c-Fn concentration increased
significantly over the next days, to reach a final value of
5.3 μg/ml (3.5-9.3) 48 hours after injury (p = 0.005).
There was a linear relationship between maximal
MMP-9 concentration measured between 6 and 12
hours and maximal c-Fn concentration measured be-
tween 24 and 48 hours (Figure 1). The higher the MMP-
9 concentration between 6 and 12 hours, the higher the
subsequent c-Fn concentration between 24 and 48 hours
(r = 0.310, n = 40, p = 0.05). Moreover, by grouping
patients according to maximal MMP-9 concentration
between 6 and 12 hours, we observed a c-Fn concentra-
tion increase over the first 48 hours only in patients with
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A trend toward higher maximal early MMP-9 concentra-
tion (+42%, p = 0.13, n = 43) or maximal late c-Fn con-
centration (+83%, p = 0.10, n = 46) was observed in
patients with a fGCS ≤ 8 as compared to patients with

















l)Relationship between MMP-9, c-Fn, f GCS and early
clinical and radiological parameters
Significantly lower fGCS and a trend toward higher
maximal early MMP-9 concentration or late c-Fn con-
centration were observed in patients with edema, with
SAH or with abnormal pupil reactions on the field ofR = 0.310, p = 0.051

































Figure 1 Relationship between early MMP-9 concentration and
subsequent c-Fn concentration. Maximal MMP-9 concentration
measured between 6 and 12 hours was plotted against maximal c-Fn

























Period of time (hours)
Figure 2 Variations of MMP-9 and c-Fn concentrations during
the 48 hours following TBI. Patients were grouped according to
the maximal MMP-9 concentration between 6 and 12 hours. Grey
boxplots: group of patients with maximal early MMP-9 concentration
≥ 20 ng/ml, white boxplots: group of patients with maximal early
MMP-9 concentration < 20 ng/ml. A and C: maximal MMP-9
concentration between 6 and 12 hours , B and D: maximal c-Fn
concentration between 24 and 48 hours. Each line represents a single
patient. ** p < 0.01, *** p < 0.001 as compared to the opposite group
of patients at the same period. ++ p < 0.01, +++ p < 0.001 as
compared to the 6–12 hour period within the same group.






ng/ml P n μg/ml P n Score P n
Oedema No 22.0 (11.8–51.5) 0.24 22 6.0 (3.5–8.9) 0.24 25 8.5 (4.0–12.0) 0.007 26
Yes 31.0 (20.6–43.9) 21 8.3 (3.9–11.2) 21 4.0 (3.0–7.5) 23
Midline shift (mm) < 5 24.2 (15.8–55.2) 0.52 29 6.6 (3.8–10.1) 0.64 30 7.0 (4.0–10.0) 0.28 33
≥ 5 25.9 (13.8–34.1) 14 6.9 (3.6–10.2) 16 4.0 (3.0–8.5) 16
SAH No 20.8 (9.8–34.1) 0.21 13 4.7 (3.0–9.2) 0.26 12 10.0 (6.0–12.0) 0.03 13
Yes 29.5 (16.3–53.8) 30 7.2 (3.9–10.2) 34 5.0 (3.0–8.5) 36
IVH No 24.2 (13.8–53.8) 0.71 33 7.6 (3.7–10.0) 0.59 35 7.0 (3.0–10.0) 0.99 37
Yes 25.9 (20.8–34.1) 10 4.0 (3.9–8.9) 11 5.5 (3.0–11.0) 12
fGCS 9-15 21.5 (11.8–28.9) 0.13 13 4.6 (3.2–7.7) 0.10 14 11.5 (10.0–14.5) 0.000 16
3-8 30.5 (16.5–53.8) 30 8.4 (3.9–10.7) 32 4.0 (3.0–7.0) 33
Pupil reaction on the field
of the accident
Normal 22.7 (12.8–47.7) 0.74 20 4.7 (2.5–5.6) 0.15 20 8.0 (4.0–12.5) 0.07 24
Abnormal 27.2 (16.1–47.1) 19 5.2 (2.7–7.3) 19 4.0 (3.0–8.0) 21
GCS14 9-15 21.6 (13.3–38.9) 0.54 23 5.3 (3.8–8.9) 0.16 25 7.5 (3.0–11.0) 0.31 26
3-8 29.5 (16.1–52.7) 20 8.3 (5.5–11.3) 21 6.0 (3.0–8.0) 23
GOSE at 3 months 5-8 21.2 (15.3–61.1) 0.72 4 4.7 (2.9–7.0) 0.34 4 7.0 (3.3–10.5) 0.94 4
1-4 28.9 (16.1–52.7) 27 7.2 (3.3–10.1) 30 7.0 (3.0–10.0) 33
Mortality at 3 months Alive 21.6 (13.3–48.9) 0.40 31 5.7 (3.5–9.6) 0.11 33 7.0 (3.0–10.0) 0.78 34
Dead 30.9 (19.6–44.3) 12 8.3 (6.0–12.3) 13 7.0 (3.0–8.5) 15
LOS ≥ 10 days for survivors in ICU No 20.6 (9.8–31.0) 0.14 17 4.0 (3.2–7.6) 0.06 18 9.0 (5.5–11.5) 0.02 19
Yes 27.2 (16.5–55.2) 17 9.1 (3.7–10.7) 16 5.0 (3.0–8.0) 18
LOS ≥ 10 days or death in ICU No 20.6 (9.8–31.0) 0.06 17 4.0 (3.2–7.6) 0.007 18 9.0 (5.5–11.5) 0.03 19
Yes 30.9 (18.6–53.8) 26 8.9 (5.4–11.3) 28 4.0 (3.0–8.0) 30
LOS ≥ 17 days for survivors in
acute hospital
No 15.5 (6.9–26.7) 0.04 16 3.9 (3.2–6.4) 0.04 17 9.0 (7.0–12.0) 0.01 18
Yes 27.2 (18.6–53.8) 17 8.8 (4.0–10.1) 17 3.0 (3.0–8.0) 18
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out SAH or with normal pupil reactions (Table 3).
Maximal early MMP-9 concentration, late c-Fn con-
centration and fGCS were similar in patients with a mid-
line shift ≥ 5 mm, with IVH or with a GOSE at 3
months ≤ 4 as compared respectively to patients with
a midline shift < 5 mm, without IVH or with a GOSE at
3 months > 4 (Table 3).
Relationship between MMP-9, c-Fn, fGCS and secondary
outcomes
ICU LOS of survivors
Statistically lower fGCS (p = 0.02, n = 37) as well as a
trend toward higher maximal early MMP-9 concentra-
tion (+32%, p = 0.14, n = 34) or late c-Fn concentration
(+127%, p = 0.06, n = 34) were observed in patients stay-
ing for 10 days or more in the ICU as compared to
patients who were alive and who left the ICU before 10
days (Table 3).Death before 3 months
A trend toward higher maximal late c-Fn concentration
was observed in patient who died before 3 months (+46%,
p = 0.11, n = 46) as compared to patients who survived.
Maximal early MMP-9 concentration and fGCS were
similar in patients who died or survived (Table 3).
Consciousness at 14 days
A trend toward higher maximal late c-Fn concentration
was also observed in patients with a GCS at 14 days ≤ 8
(+57%, p = 0.16, n = 46) as compared to patients with a
GCS at 14 days > 8. Maximal early MMP-9 concentra-
tion and fGCS were similar in patients with a GCS at 14
days ≤ 8 or a GCS at14 days > 8 (Table 3).
GOSE at 3 months
No relationship was observed between MMP-9, c-Fn
concentrations or fGCS and the Glasgow Outcome Scale




















































Figure 3 ROC curves and relationship between MMP-9 and c-Fn
concentrations and ICU LOS or death. A: Roc curve analysis of
maximal MMP-9 concentration between 6 and 12 hours, maximal
c-Fn concentration] between 24 and 48 hours and fGCS for the
prediction of ICU LOS ≥ 10 days or death in the ICU. Plain line:
maximal c-Fn concentration between 24 and 48 hours; dash line:
maximal MMP-9 concentration between 6 and 12 hours; dot line:
fGCS; diagonal line: reference line. B: Relationship between MMP-9
and c-Fn concentrations and ICU LOS or death. Maximal MMP-9
between 6 and 12 hours was plotted against maximal c-Fn
concentrations between 24 and 48 hours. Horizontal line: 7.65 μg/ml
threshold; vertical line: 21.55 ng/ml threshold; circles: survivors
leaving the ICU before 10 days; squares: survivors leaving the ICU at
10 days or later; triangles: patients who died in the ICU.
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composite endpoint
Statistically lower fGCS (p = 0.03, n = 49) and higher
maximal late c-Fn concentration (+123%, p = 0.007, n = 46)
as well as a strong trend toward higher maximal early
MMP-9 concentration (+50%, p = 0.06, n = 43) were
observed in patients dying or staying for 10 days or more in
the ICU as compared to patients who were alive and who
left the ICU before 10 days (Table 3).
ROC curves for discriminating patients who died or
stayed longer than 9 days in the ICU (Figure 3A) showed
a slightly higher area under the curve (AUC) for max-
imal late c-Fn concentration (AUC = 0.737) than fGCS
(AUC = 0.682) or maximal early MMP-9 concentration
(AUC = 0.674). However, the ROC curves were not
statistically different (bootstap test).
There was a 1.8 greater probability of dying or of stay-
ing longer than 9 days in the ICU for patients with a
maximal late c-Fn concentration ≥ 7.7 μg/ml (OR, 5.4;
95% CI, 1.4-20.8; p = 0.01; sensitivity/specificity: 60.7%/
77.8%, Figure 3B), and a 2.0 greater probability for
patients with a maximal early MMP-9 ≥ 21.6 ng/ml (OR,
5.0; 95% CI, 1.3-18.6; p = 0.02; sensitivity/specificity:
73.1%/64.7%, Figure 3B). The risk of dying or of staying
longer than 9 days in the ICU was 1.9 time higher for
patients with a fGCS ≤ 8 as compared to patients with a
fGCS > 8 (OR, 4.4; 95% CI, 1.2-15.8; p = 0.02; sensitivity/
specificity: 80.0%/52.6%).
The association of c-Fn or MMP-9 with fGCS for pre-
dicting mortality or a LOS longer than 9 days in the ICU
decreased dramatically the sensitivity of the tests (maximal
late c-Fn concentration ≥ 7.7 μg/ml and fGCS ≤ 8: OR, 5.0;
95% CI, 1.2-20.8; p = 0.03; sensitivity/specificity: 48.3%/
84.2%; maximal early MMP-9 ≥ 21.6 ng/ml and fGCS ≤ 8:
OR, 4.0; 95% CI, 1.1-15.4; p = 0.04; sensitivity/specificity:
53.6%/77.8%).
Discussion
Our data confirm the initial raise of plasma MMP-9 con-
centration after TBI in humans as reported by other
investigators based on animal models. To our know-
ledge, this is the first report of a raise of plasma c-Fn
concentration in TBI patients and first observation of a
temporal relationship between plasma MMP-9 concen-
tration and plasma c-Fn concentration. Furthermore it is
the first time that a correlation analysis is performed be-
tween MMP-9, c-Fn, fGCS and TBI patient outcome.
MMP-9, c-Fn and fGCS have similar predictive values
for the composite patient-relevant endpoint ICU LOS
and death. In contrast, associating the blood markers
with fGCS for predicting ICU LOS and death rendered
the tests ineffective with sensitivities close to 0.5.
In a rat TBI model, the local brain MMP-9 level was
highest at 24 h after trauma with a second peak at 72hours [24]. In a second rat TBI model, the local brain
ProMMP-9 (the latent form of MMP-9) was highest at
6 h and lower levels were observed at 24 h [25]. In a
third rat TBI model, the local brain MMP-9 activity was
highest at 24 hours [26]. In our patients, the maximal
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ference may be species-related or due to different
trauma mechanisms.
Early MMP-9 increase may cause BBB degradation
leading to later c-Fn release, therefore, a relationship be-
tween maximal early MMP-9 concentration and subse-
quent maximal c-Fn concentration is not surprising.
This temporal profile of MMP-9 and c-Fn concentra-
tions supports a role for MMP-9 in fibril degradation
after TBI. Both MMP-9 and c-Fn concentrations tend to
be higher in patients with brain oedema. The cause of
MMP-9 increase after TBI has not been investigated in
our study but could be related to inflammation and neu-
trophil activation [41,42] after injury. Activated MMP-9
degrades c-Fn, which is released into circulation as a
marker of clinical severity as suggested by the trend to-
ward higher maximal c-Fn concentration between 24
and 48 hours in patients with a GCS at 14 days ≤ 8 and
in patients that died before 3 months.
The risk of longer ICU LOS (≥ 10 days) for survivors
or death in the ICU was statistically increased in patients
with a maximal MMP-9 concentration equal of higher
than 21.6 ng/ml between 6 and 12 hours after TBI or
with a maximal c-Fn equal or higher than 7.7 μg/ml be-
tween 24 and 48 hours. A statistically significant rela-
tionship between this composite endpoint and fGCS
equal or lower than 8 was also observed. Patients with
severe TBI have two pattern of LOS in hospital: Non-
survivors with a short median hospital LOS of 3 days
and survivors with a long median hospital stay of 24
days [43]. ICU LOS is directly related to the clinical con-
dition of the patients. MMP-9 and c-Fn concentration
measurements might be more objective and reliable
tools than fGCS for the prediction of the ICU LOS or
death because the considerable inaccuracy in GCS scor-
ing in daily practice [10].
Early prognostic factors of hospital LOS after severe
TBI were rarely investigated but could have clinical
implications. Apart the short LOS of patients with fatal
injuries [43], post-traumatic sepsis and pneumonia were
considered as risk factors for prolonged hospital LOS
[44]. Early predictors such as MMP-9 and c-Fn may be
useful for enhanced in-hospital health care resources
planning and improved patient and family information.
Furthermore, ICU LOS is a relevant predictor for rehabili-
tation LOS after traumatic brain injury underlying the
desirability of improved hospital LOS prediction [45].
This study has several limitations. First, the significant
relationship between early brain-derived biomarkers
sampled in blood and the composite endpoint will not
mean causality between the degree of TBI and patients’
outcome. Second, inclusion criteria was not defined with
the physiological instrument GCS, but with the anatom-
ical instrument HAIS. This cohort of 49 patients had,therefore, included patients with different states of con-
sciousness with a median fGCS 7 and median GCS 3 in
the emergency department. The inclusion criteria of this
study was based on the AIS trauma system to avoid
biases related to clinical interventions and inter-rater
variability [10]. Third, our results have to be considered
as a proof-of-concept. In contrast to animal studies,
patients with TBI have a heterogeneous brain injury pat-
tern and different sizes of injuries with different quantity
of release of biomarkers making relationship with clin-
ical outcomes less evident. The absence of relationship
for the component end points alone and the other sec-
ondary outcomes in our cohort of 49 patients will not
exclude any association in a more homogeneous or lar-
ger population. Probably, a very high number of patients
would be needed to test association for a single patient-
relevant outcome. Composite endpoint provides evi-
dence for a hypothesis with fewer patients, but may be
criticised. However, there is a biological basis for our
results: Brain edema, a major cause of secondary injury
after TBI [46,47], is partly due to MMP-9 activation and
degradation of components of the basal lamina such as
c-Fn, leading to blood–brain barrier disruption [20] and
to severe TBI with prolonged ICU stay and death.
The clinical relevance of our results is actually limited
despite an association between the biomarkers MMP-9
and c-Fn and a clinical composite endpoint. However, this
clinical study has confirmed some postulated mechanisms
in the early phase of TBI the first time in humans. There-
fore, there is a potential that these early plasmatic biomar-
kers may predict patients’ outcome. Validation of our
results with other more homogenous and larger TBI
populations is needed before clinical implementation may
be considered.
Conclusion
In conclusion, the plasma biomarkers MMP-9 and c-Fn
can be measured in the early phase after TBI and are
predictive for the composite endpoint of ICU LOS in
survivors and death but not for consciousness at 14 days
nor outcome at 3 months.
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